Company intelligence / Profile preview
Pulmatrix, Inc.
Framingham, Massachusetts, United Statespulmatrix.com ↗
- Ownership
- Public · PULM
- Employees
- ~2
- Development stage
- Phase 2
01
Overview
Developing multiple clinical candidates including PUR1800 (completed Phase 1b for COPD), PUR1900 (for ABPA in asthma and cystic fibrosis patients), and PUR3100 (in Phase 1 for acute migraine)
- Therapeutic areas
- PulmonologyNeurology
- Modalities
- Inhaled therapeutic productsdry powder formulations
- Industry
- Biotech
02
Drug pipeline
9 assets8 more assets in the full pipeline.
03
Partnerships
License agreement with RespiVert Ltd.
04
Financials
- Market cap
- $5.1M
- Total revenue
- $0
- Enterprise value
- $2.9M
Beyond the preview
Go deeper on Pulmatrix, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pulmatrix, Inc..